State Street
AVBP icon

State Street’s ArriVent BioPharma AVBP Stock Holding History

State Street’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8M Buy
1,421,415
+329,435
+30% +$7.44M ﹤0.01% 1964
2025
Q4 		$22M Buy
1,091,980
+64,352
+6% +$1.34M ﹤0.01% 2215
2025
Q3 		$19M Buy
1,027,628
+286,836
+39% +$5.64M ﹤0.01% 2285
2025
Q2 		$16.1M Sell
740,792
-26,948
-4% -$560K ﹤0.01% 2309
2025
Q1 		$14.2M Sell
767,740
-46,351
-6% -$1.13M ﹤0.01% 2314
2024
Q4 		$21.7M Buy
814,091
+337,282
+71% +$9.68M ﹤0.01% 2190
2024
Q3 		$11.2M Buy
476,809
+323,186
+210% +$7.34M ﹤0.01% 2532
2024
Q2 		$2.85M Buy
153,623
+31,359
+26% +$559K ﹤0.01% 3169
2024
Q1 		$2.18M Buy
+122,264
New +$2.47M ﹤0.01% 3254

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's AVBP Position: Q1 2026 in Review

State Street increased its ArriVent BioPharma (AVBP) stake by 30% in Q1 2026, buying an estimated $7.44M and bringing the position to 1,421,415 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

State Street first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • State Street held 1,421,415 shares of ArriVent BioPharma worth $32.8M as of Q1 2026.
  • State Street bought 329,435 ArriVent BioPharma shares in Q1 2026, an estimated $7.44M.
  • ArriVent BioPharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1964 holding.
  • State Street first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.